Last 48 quarters of trend data · Healthcare · Diagnostics & Lab Testing
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 10.05 | 5.55 | 5.30 | — | 2.84 | — | 5.17 | 26.59 | — | 3.58 | — | 6.43 | 6.65 | 24.62 | — | 51.62 | 3.78 | — | — | — | — |
| — | — | +2.5% | — | — | — | — | +313.6% | — | -85.4% | — | -87.5% | +75.7% | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.96 | 3.88 | 3.02 | 3.17 | 2.95 | 2.89 | 2.52 | 2.91 | 3.44 | 3.60 | 3.04 | 4.04 | 3.41 | 4.14 | 4.08 | 5.26 | 4.29 | 4.55 | 5.33 | 6.02 | 7.71 |
| — | +34.1% | +19.9% | +9.1% | -14.3% | -19.8% | -17.0% | -28.0% | +0.9% | -13.0% | -25.7% | -23.2% | -20.4% | -9.0% | -23.4% | -12.6% | -44.4% | -39.6% | -21.3% | +1.5% | +38.6% | |
| P/B Ratio | 1.40 | 1.34 | 1.10 | 1.10 | 1.10 | 1.12 | 0.92 | 1.02 | 1.40 | 1.25 | 1.14 | 1.09 | 1.06 | 1.24 | 1.32 | 1.46 | 1.30 | 1.47 | 1.65 | 1.66 | 1.65 |
| — | +19.5% | +19.1% | +7.6% | -21.6% | -10.4% | -19.4% | -6.5% | +31.5% | +0.5% | -13.2% | -25.3% | -18.3% | -15.2% | -20.3% | -11.9% | -21.1% | -0.2% | -1.3% | +1.9% | -7.2% | |
| P/FCF | 31.21 | 39.02 | 29.51 | 24.05 | 17.18 | 21.16 | 23.20 | 17.82 | 28.30 | 23.41 | 35.02 | 83.32 | 59.95 | 48.82 | 43.87 | 57.09 | 72.02 | — | 102.60 | 242.01 | 49.28 |
| — | +84.4% | +27.2% | +35.0% | -39.3% | -9.6% | -33.7% | -78.6% | -52.8% | -52.0% | -20.2% | +45.9% | -16.8% | — | -57.2% | -76.4% | +46.1% | — | +177.3% | +428.1% | +175.3% | |
| EV / EBITDA | 15.81 | — | 3.95 | 27.95 | 21.99 | 19.32 | 16.16 | 30.97 | 23.42 | 25.01 | 15.85 | 27.14 | 17.09 | 20.54 | 20.58 | 35.27 | 19.97 | 26.09 | 23.87 | 24.28 | 39.74 |
| — | — | -75.6% | -9.8% | -6.1% | -22.8% | +2.0% | +14.1% | +37.1% | +21.8% | -23.0% | -23.0% | -14.5% | -21.3% | -13.8% | +45.3% | -49.7% | -4.7% | -15.1% | -17.1% | +95.9% | |
| EV / EBIT | 41.66 | 5.03 | 3.95 | — | 2.44 | — | 4.46 | 20.07 | — | 2.96 | — | 5.38 | 5.85 | 19.10 | — | 39.02 | 3.06 | — | — | — | — |
| — | — | -11.5% | — | — | — | — | +272.8% | — | -84.5% | — | -86.2% | +91.3% | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.0% | 50.1% | 53.1% | 52.3% | 49.8% | 52.6% | 53.0% | 52.3% | 51.2% | 54.8% | 55.6% | 53.4% | 53.7% | 53.1% | 53.2% | 53.5% | 54.4% | 54.9% | 57.3% | 57.5% | 54.7% |
| — | -4.8% | +0.2% | -0.0% | -2.8% | -4.0% | -4.7% | -2.2% | -4.6% | +3.2% | +4.5% | -0.2% | -1.2% | -3.3% | -7.1% | -6.9% | -0.6% | -6.2% | +2.1% | +4.3% | -6.1% | |
| Operating Margin | 10.5% | -7.6% | 11.2% | 5.8% | 8.9% | 10.2% | 11.8% | 4.0% | 8.7% | 9.9% | 15.9% | 8.5% | 14.4% | 14.4% | 13.2% | 9.1% | 16.2% | 13.6% | 17.4% | 20.9% | 14.6% |
| — | -174.5% | -5.7% | +42.3% | +2.2% | +2.5% | -25.6% | -52.5% | -39.1% | -31.0% | +20.8% | -6.9% | -11.7% | +5.6% | -24.4% | -56.3% | +11.3% | -35.1% | -0.2% | +50.7% | -34.2% | |
| Net Margin | 29.4% | 69.9% | 57.1% | -89.0% | 103.9% | -52.4% | 48.8% | 10.9% | -107.2% | 100.5% | -339.2% | 62.9% | 51.3% | 16.8% | -170.6% | 10.2% | 114.1% | -24.1% | -134.2% | -481.0% | -214.8% |
| — | +233.4% | +17.0% | -914.3% | +196.9% | -152.1% | +114.4% | -82.6% | -308.9% | +498.1% | -98.8% | +516.9% | -55.0% | +169.7% | -27.2% | +102.1% | +153.1% | -104.6% | -205.1% | -457.7% | -302.1% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.8% | 6.2% | 5.3% | -7.4% | 10.1% | -4.9% | 4.6% | 1.0% | -10.2% | 9.2% | -27.4% | 4.3% | 4.1% | 1.3% | -12.8% | 0.7% | 9.2% | -1.9% | -9.7% | -28.2% | -10.8% |
| — | +225.9% | +15.1% | -862.8% | +199.6% | -153.9% | +116.8% | -77.6% | -349.8% | +626.6% | -114.3% | +506.4% | -55.8% | +166.7% | -31.5% | +102.5% | +185.1% | -106.5% | -217.9% | -395.7% | -220.9% | |
| ROA | 7.6% | 4.4% | 3.7% | -5.2% | 7.1% | -3.4% | 3.2% | 0.7% | -7.2% | 6.4% | -19.4% | 3.1% | 2.9% | 0.9% | -9.1% | 0.5% | 6.5% | -1.3% | -6.9% | -20.9% | -8.3% |
| — | +227.0% | +15.1% | -863.9% | +199.1% | -153.3% | +116.6% | -78.0% | -348.0% | +623.3% | -114.3% | +507.2% | -55.7% | +167.0% | -32.2% | +102.4% | +178.2% | -105.9% | -208.9% | -388.1% | -224.2% | |
| ROIC | 2.6% | -0.5% | 0.7% | 0.3% | 0.6% | 0.6% | 0.7% | 0.2% | 0.5% | 0.6% | 0.9% | 0.4% | 0.8% | 0.7% | 0.7% | 0.4% | 0.9% | 0.7% | 0.9% | 0.9% | 0.6% |
| — | -172.7% | -5.2% | +33.2% | +4.4% | +5.1% | -13.9% | -39.9% | -28.4% | -17.9% | +28.2% | -9.7% | -14.2% | -0.8% | -24.0% | -51.8% | +57.0% | -19.8% | -0.1% | +17.5% | -60.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.18 | 0.17 | 0.20 | 0.21 | 0.21 | 0.20 | 0.21 | 0.21 | 0.19 | 0.21 | 0.15 | 0.16 | 0.17 | 0.16 | 0.14 | 0.14 | 0.16 | 0.16 | 0.14 | 0.02 |
| — | -13.4% | -15.0% | -1.9% | -1.8% | +11.7% | -4.0% | +32.6% | +30.1% | +11.0% | +25.5% | +9.3% | +11.4% | +2.4% | +4.9% | +2.6% | +784.5% | +960.5% | +711.7% | +533.1% | -28.6% | |
| Debt / EBITDA | 3.51 | — | 2.22 | 18.38 | 14.66 | 12.62 | 11.95 | 22.16 | 12.77 | 13.43 | 10.10 | 14.02 | 9.32 | 10.11 | 9.39 | 12.85 | 8.23 | 10.85 | 8.55 | 7.81 | 1.59 |
| — | — | -81.4% | -17.1% | +14.8% | -6.1% | +18.3% | +58.0% | +37.0% | +32.9% | +7.6% | +9.1% | +13.3% | -6.8% | +9.8% | +64.6% | +418.1% | +821.1% | +545.6% | +384.5% | +48.7% | |
| Current Ratio | 5.62 | 3.18 | 3.14 | 3.21 | 5.62 | 5.44 | 5.12 | 5.99 | 6.48 | 6.14 | 6.28 | 6.57 | 5.83 | 5.64 | 5.39 | 5.56 | 5.55 | 5.50 | 5.30 | 5.10 | 2.92 |
| — | -41.6% | -38.6% | -46.5% | -13.2% | -11.3% | -18.4% | -8.7% | +11.1% | +8.8% | +16.4% | +18.1% | +5.0% | +2.5% | +1.9% | +9.1% | +90.0% | +45.0% | +35.8% | +42.9% | -13.7% | |
| Quick Ratio | 4.19 | 2.37 | 2.33 | 2.37 | 4.19 | 3.94 | 3.67 | 4.43 | 4.85 | 4.52 | 4.63 | 4.89 | 4.34 | 4.25 | 4.06 | 4.28 | 4.29 | 4.30 | 4.22 | 4.16 | 2.08 |
| — | -39.9% | -36.4% | -46.6% | -13.7% | -12.8% | -20.7% | -9.2% | +11.9% | +6.4% | +14.0% | +14.1% | +1.2% | -1.2% | -3.9% | +2.9% | +105.9% | +48.9% | +46.7% | +61.6% | -13.3% | |
| Interest Coverage | 21.32 | 44.80 | — | -55.08 | 77.79 | -34.05 | 33.86 | 7.95 | -73.59 | 71.78 | -226.19 | 41.00 | 35.66 | 12.06 | -120.56 | 7.88 | 94.41 | -16.78 | -112.83 | -1078.06 | -5598.05 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BIO stock.
Bio-Rad Laboratories, Inc.'s current P/E is 10.1x. The average P/E over the last 3 quarters is 4.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bio-Rad Laboratories, Inc.'s current operating margin is 10.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bio-Rad Laboratories, Inc.'s business trajectory between earnings reports.